Summary of patient characteristics
| Lesogaberan (n=122) | Placebo (n=122) | |
| Men, n (%) | 71 (58) | 91 (75) |
| Mean age, years (SD) | 51.1 (11.9) | 48.7 (12.6) |
| Mean body mass index, kg/m2 (SD) | 27.1 (3.7) | 27.0 (3.0) |
| Duration of GORD, n (%) | ||
| 0.5 to <1 years | 7 (6) | 6 (5) |
| 1 to <5 years | 46 (38) | 44 (36) |
| 5 to <10 years | 31 (25) | 34 (28) |
| ≥10 years | 38 (31) | 38 (31) |
| History of reflux oesophagitis, n (%) | 64 (52.5) | 74 (61) |
| History of hiatal hernia, n (%) | 60 (49) | 64 (52.5) |
| Helicobacter pylori-positive, n (%) | 32 (26) | 30 (25) |
| Symptom frequency at baseline, n (%)* | ||
| Daily | 91 (75) | 90 (77) |
| 5–6 days/week | 23 (19) | 14 (12) |
| 3–4 days/week | 5 (4) | 8 (7) |
| Moderate to severe symptoms, n (%)* † | 98 (81) | 108 (92) |
| PPI dose (mg) at baseline, n (%) | ||
| Esomeprazole | ||
| 10 mg | 1 (1) | |
| 20 mg | 26 (21) | 31 (25) |
| 40 mg | 11 (9) | 23 (19) |
| Lansoprazole | ||
| 15 mg | ||
| 30 mg | 14 (11) | 3 (2) |
| 60 mg | 1 (1) | 8 (7) |
| Omeprazole | ||
| 10 mg | 1 (1) | |
| 20 mg | 25 (20) | 16 (13) |
| 40 mg | 2 (2) | 3 (2) |
| 80 mg | 1 (1) | |
| Pantoprazole | ||
| 20 mg | 7 (6) | 3 (2) |
| 40 mg | 17 (14) | 19 (16) |
| 80 mg | 3 (2) | |
| Rabeprazole | ||
| 10 mg | 2 (2) | 3 (2) |
| 20 mg | 9 (7) | 5 (4) |
| 40 mg | 3 (2) | 4 (3) |